A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

Summary

The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.

Timeline

Start

2025-07

Primary completion

2026-04

Completion

2027-04

Outcome

Outcome not reported

Stopped (Enrollment): “Study sponsor, Daiichi, decided to close for mult reasons, including drug near expiration, lack of enrollment, and their priority changes.”

Drugs

Indications